ATE399535T1 - Verfahren zur herstellung von mikropartikeln mit einem ausgewählten polymermolekulargewicht - Google Patents

Verfahren zur herstellung von mikropartikeln mit einem ausgewählten polymermolekulargewicht

Info

Publication number
ATE399535T1
ATE399535T1 AT01928630T AT01928630T ATE399535T1 AT E399535 T1 ATE399535 T1 AT E399535T1 AT 01928630 T AT01928630 T AT 01928630T AT 01928630 T AT01928630 T AT 01928630T AT E399535 T1 ATE399535 T1 AT E399535T1
Authority
AT
Austria
Prior art keywords
molecular weight
selected polymer
polymer molecular
polymer
producing microparticles
Prior art date
Application number
AT01928630T
Other languages
English (en)
Inventor
Steven Wright
Michael RICKEY
J Ramstack
Shawn Lyons
Joyce Hotz
Original Assignee
Alkermes Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24298824&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE399535(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alkermes Inc filed Critical Alkermes Inc
Application granted granted Critical
Publication of ATE399535T1 publication Critical patent/ATE399535T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • B01J13/02—Making microcapsules or microballoons

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Polyamides (AREA)
AT01928630T 2000-05-19 2001-04-19 Verfahren zur herstellung von mikropartikeln mit einem ausgewählten polymermolekulargewicht ATE399535T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/575,075 US6264987B1 (en) 2000-05-19 2000-05-19 Method for preparing microparticles having a selected polymer molecular weight

Publications (1)

Publication Number Publication Date
ATE399535T1 true ATE399535T1 (de) 2008-07-15

Family

ID=24298824

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01928630T ATE399535T1 (de) 2000-05-19 2001-04-19 Verfahren zur herstellung von mikropartikeln mit einem ausgewählten polymermolekulargewicht

Country Status (12)

Country Link
US (6) US6264987B1 (de)
EP (3) EP1282404B1 (de)
JP (1) JP4903344B2 (de)
AT (1) ATE399535T1 (de)
AU (2) AU2001255465B2 (de)
CA (1) CA2405787C (de)
CY (2) CY1110403T1 (de)
DE (1) DE60134640D1 (de)
DK (2) DK1282404T3 (de)
ES (2) ES2305071T3 (de)
PT (2) PT1925297E (de)
WO (1) WO2001089482A2 (de)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6194006B1 (en) * 1998-12-30 2001-02-27 Alkermes Controlled Therapeutics Inc. Ii Preparation of microparticles having a selected release profile
US6264987B1 (en) * 2000-05-19 2001-07-24 Alkermes Controlled Therapeutics Inc. Ii Method for preparing microparticles having a selected polymer molecular weight
US7666445B2 (en) 2000-10-20 2010-02-23 The Trustees Of The University Of Pennsylvania Polymer-based surgically implantable haloperidol delivery systems and methods for their production and use
AU2000202A (en) * 2000-10-31 2002-05-15 Pr Pharmaceuticals Inc Methods and compositions for enhanced delivery of bioactive molecules
US7357891B2 (en) 2001-10-12 2008-04-15 Monosol Rx, Llc Process for making an ingestible film
US8765167B2 (en) 2001-10-12 2014-07-01 Monosol Rx, Llc Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US8900497B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for making a film having a substantially uniform distribution of components
US8900498B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for manufacturing a resulting multi-layer pharmaceutical film
US10285910B2 (en) 2001-10-12 2019-05-14 Aquestive Therapeutics, Inc. Sublingual and buccal film compositions
US11207805B2 (en) 2001-10-12 2021-12-28 Aquestive Therapeutics, Inc. Process for manufacturing a resulting pharmaceutical film
US8603514B2 (en) 2002-04-11 2013-12-10 Monosol Rx, Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
US20110033542A1 (en) 2009-08-07 2011-02-10 Monosol Rx, Llc Sublingual and buccal film compositions
US20190328679A1 (en) 2001-10-12 2019-10-31 Aquestive Therapeutics, Inc. Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
AU2002366710A1 (en) * 2001-12-20 2003-07-09 The Government Of The United States Of America As Represented By The Secretary Of The Department Of USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS
US20030177143A1 (en) * 2002-01-28 2003-09-18 Steve Gardner Modular bioinformatics platform
IL164152A0 (en) * 2002-03-26 2005-12-18 Teva Pharma Drug microparticles
WO2004005325A2 (en) * 2002-07-10 2004-01-15 The Ohio State University Research Foundation Antigen-polymer compositions
DE10235556A1 (de) * 2002-08-03 2004-02-19 Hf Arzneimittelforschung Gmbh Medikament und Verfahren zur Verringerung des Alkohol- und/oder Tabakkonsums
AU2003286512A1 (en) * 2002-10-18 2004-05-04 Charles N. Ellis Method for rating severity of psoriasis
WO2004064752A2 (en) * 2003-01-22 2004-08-05 Alkermes Controlled Therapeutics, Inc. Method of preparing sustained release microparticles
BRPI0409032A (pt) * 2003-04-10 2006-05-02 Pr Pharmaceuticals método para a produção de micropartìculas à base de emulsão
US20070207211A1 (en) * 2003-04-10 2007-09-06 Pr Pharmaceuticals, Inc. Emulsion-based microparticles and methods for the production thereof
US7279579B2 (en) * 2003-06-04 2007-10-09 Alkermes, Inc. Polymorphic forms of naltrexone
CN102935069A (zh) * 2003-07-15 2013-02-20 Pr药品有限公司 控释组合物的制备方法
CA2819769C (en) 2003-07-18 2016-06-28 Oakwood Laboratories, L.L.C. Prevention of molecular weight reduction of the polymer, impurity formation and gelling in polymer compositions
US8900636B2 (en) * 2003-07-23 2014-12-02 Evonik Corporation Controlled release compositions
US6987111B2 (en) * 2003-08-06 2006-01-17 Alkermes Controlled Therapeutics, Ii Aripiprazole, olanzapine and haloperidol pamoate salts
US20070275877A1 (en) * 2003-08-29 2007-11-29 Amylin Pharmaceuticals, Inc. Methods for Treating or Ameliorating Ghrelin-Associated Diseases and Disorders
US8221778B2 (en) 2005-01-12 2012-07-17 The Trustees Of The University Of Pennsylvania Drug-containing implants and methods of use thereof
EP2633853A1 (de) * 2004-01-12 2013-09-04 The Trustees of The University of Pennsylvania Langzeitabgabe von Lieferungsformulierungen und Verwendungsverfahren dafür
US8329203B2 (en) 2004-01-12 2012-12-11 The Trustees Of The University Of Pennsylvania Drug-containing implants and methods of use thereof
EP2233497A3 (de) * 2004-02-11 2011-01-12 Amylin Pharmaceuticals, Inc. Peptide der amylin Familie, Verfahren zu deren Herstellung und Verwendung
KR20140104986A (ko) * 2004-02-17 2014-08-29 트랜스셉트 파마슈티칼스, 인코포레이티드 구강 점막을 가로지르는 수면제 전달용 조성물 및 이의 사용 방법
US7399744B2 (en) * 2004-03-04 2008-07-15 Amylin Pharmaceuticals, Inc. Methods for affecting body composition
US20050245541A1 (en) * 2004-03-19 2005-11-03 Elliot Ehrich Methods for treating alcoholism
US20050245461A1 (en) * 2004-03-19 2005-11-03 Elliot Ehrich Methods for treating alcoholism
US7919499B2 (en) * 2004-04-22 2011-04-05 Alkermes, Inc. Naltrexone long acting formulations and methods of use
US20050260272A1 (en) * 2004-05-05 2005-11-24 Alkermes Controlled Therapeutics, Inc. Method of forming microparticles that include a bisphosphonate and a polymer
ES2325773T5 (es) 2004-11-01 2014-02-24 Amylin Pharmaceuticals, Llc. Tratamiento de la obesidad y de los trastornos relacionados
EP3000826A1 (de) 2004-12-13 2016-03-30 Amylin Pharmaceuticals, LLC Motive der bauchspeicheldrüsen-polypeptid familie, polypeptide und methoden unter verwendung derselben
US20080213593A1 (en) * 2005-01-21 2008-09-04 President And Fellows Of Harvard College Systems And Methods For Forming Fluidic Droplets Encapsulated In Particles Such As Colloidal Particles
EP1853627A2 (de) 2005-02-11 2007-11-14 Amylin Pharmaceuticals, Inc. Gip-analog und hybridpolypeptide mit auswählbaren eigenschaften
WO2006105527A2 (en) 2005-03-31 2006-10-05 Amylin Pharmaceuticals, Inc. Amylin and amylin agonists for treating psychiatric diseases and disorders
NZ563979A (en) * 2005-05-25 2011-02-25 Transcept Pharmaceuticals Inc Solid compositions and methods for treating middle-of-the night insomnia
US20070287740A1 (en) * 2005-05-25 2007-12-13 Transcept Pharmaceuticals, Inc. Compositions and methods of treating middle-of-the night insomnia
US20070225322A1 (en) * 2005-05-25 2007-09-27 Transoral Pharmaceuticals, Inc. Compositions and methods for treating middle-of-the night insomnia
MX362908B (es) * 2005-07-18 2019-02-21 Univ Pennsylvania Implantes que contienen fármacos y métodos de uso de los mismos.
AU2006285127A1 (en) * 2005-08-30 2007-03-08 Acologix, Inc. Regulation of mineral and skeletal metabolism
WO2007041190A2 (en) * 2005-09-30 2007-04-12 The University Of Iowa Research Foundation Polymer-based delivery system for immunotherapy of cancer
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
ES2616296T3 (es) * 2005-12-02 2017-06-12 (Osi) Eyetech, Inc. Micropartículas de liberación controlada
ES2389747T3 (es) 2007-02-05 2012-10-31 Amylin Pharmaceuticals, Inc. Péptidos FN-38 para su uso en el tratamiento de desórdenes psicóticos y de ansiedad
JP2010531807A (ja) 2007-05-25 2010-09-30 トルマー セラピューティクス， インコーポレイテッド リスペリドン化合物の徐放送達製剤
WO2010030763A2 (en) 2008-09-10 2010-03-18 Bind Biosciences, Inc. High throughput fabrication of nanoparticles
CA2749993C (en) * 2009-01-23 2016-12-20 Surmodics Pharmaceuticals, Inc. Continuous double emulsion process for making microparticles
US20100196436A1 (en) * 2009-01-30 2010-08-05 Gooberman Lance L Implants containing disulfiram and an anti-inflammatory agent
US8791093B2 (en) * 2009-05-29 2014-07-29 Lance L. Gooberman Pharmaceutical delivery systems for treatment of substance abuse and other addictions
WO2011088152A1 (en) 2010-01-12 2011-07-21 Portola Pharmaceuticals, Inc. Pharmaceutical composition and dosage forms of elinogrel and methods of use thereof
GB2513060B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
EA201390450A1 (ru) 2010-09-28 2013-07-30 Амилин Фармасьютикалс, Ллк. Полипептиды с увеличенной продолжительностью действия
PT2621515T (pt) 2010-09-28 2017-07-12 Aegerion Pharmaceuticals Inc Polipéptido quimérico de leptina de foca-ser humano com solubilidade aumentada
US9149959B2 (en) 2010-10-22 2015-10-06 Monosol Rx, Llc Manufacturing of small film strips
US8987285B2 (en) 2010-12-03 2015-03-24 Portola Pharmaceuticals, Inc. Pharmaceutical compositions, dosage forms and new forms of the compound of formula (I), and methods of use thereof
CN104271588B (zh) 2011-07-08 2017-10-10 安米林药品有限责任公司 具有增强的作用持续时间和降低的免疫原性的工程改造的多肽
US20140256621A1 (en) 2011-07-08 2014-09-11 Astrazeneca Pharmaceuticals Lp Engineered poypeptides having enhanced duration of action and reduced immunogenicity
BRPI1106938A2 (pt) * 2011-10-17 2015-12-08 Fbm Indústria Farmacêutica Ltda composição farmacêutica de liberação controlada contendo naltrexona e topiramato
RU2471478C1 (ru) * 2011-12-08 2013-01-10 Станислав Анатольевич Кедик Фармацевтическая композиция для лечения алкоголизма, наркомании и токсикомании с улучшенным профилем высвобождения налтрексона
SI3010962T2 (sl) 2013-06-20 2023-04-28 Pharmathen S.A. Priprava polilaktid-poliglikolidnih mikrodelcev, ki imajo sigmoidni profil sproščanja
WO2014202214A1 (en) 2013-06-20 2014-12-24 Pharmathen S.A. Preparation of polylactide-polyglycolide microparticles having a sigmoidal release profile
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
AU2015341490C1 (en) 2014-11-07 2021-03-11 Indivior Uk Limited Buprenorphine dosing regimens
CN108368502B (zh) 2015-06-03 2022-03-18 内布拉斯加大学董事委员会 使用单链dna的dna编辑
EP3348268A4 (de) * 2015-09-07 2019-04-10 Nipro Corporation Risperidonhaltige mikrokapsel, verfahren zur herstellung davon und freisetzungssteuerungsverfahren
US11273131B2 (en) 2016-05-05 2022-03-15 Aquestive Therapeutics, Inc. Pharmaceutical compositions with enhanced permeation
JP7653218B2 (ja) 2016-05-05 2025-03-28 アクエスティブ セラピューティクス インコーポレイテッド 送達増強エピネフリン組成物
US12433850B2 (en) 2016-05-05 2025-10-07 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine and prodrug compositions
US12427121B2 (en) 2016-05-05 2025-09-30 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine compositions
WO2018031771A1 (en) 2016-08-11 2018-02-15 University Of Iowa Research Foundation CATIONIC CaMKII INHIBITING NANOPARTICLES FOR THE TREATMENT OF ALLERGIC ASTHMA
US10646484B2 (en) 2017-06-16 2020-05-12 Indivior Uk Limited Methods to treat opioid use disorder
CN109718212A (zh) * 2017-10-30 2019-05-07 浙江圣兆药物科技股份有限公司 一种减少利培酮微球中低挥发溶剂苯甲醇的方法
CN113164395A (zh) 2018-10-15 2021-07-23 株式会社钟根堂 注射用长效纳屈酮微粒组合物
WO2020135576A1 (en) * 2018-12-27 2020-07-02 Alar Pharmaceuticals Inc. Naltrexone injectable sustained release formulation
KR102072968B1 (ko) * 2019-05-28 2020-02-04 주식회사 울트라브이 생분해성 고분자 미세 입자의 제조 방법 및 조직 수복용 생분해성 재료
EP4045152A1 (de) 2019-10-15 2022-08-24 Cornell University Verfahren zur modulation des expressionsniveaus aus einer gentherapieexpressionskassette
EP4045653A1 (de) 2019-10-16 2022-08-24 Cornell University Gentherapie für morbus alzheimer
US20230001017A1 (en) 2019-10-28 2023-01-05 University Of Lowa Research Foundation Formulation for delivery of lubricin gene
JP2023502515A (ja) 2019-11-25 2023-01-24 コーネル・ユニバーシティー Ａｐｏｅ遺伝子療法
CN113546060B (zh) * 2020-04-08 2023-04-07 江苏长泰药业有限公司 一种纳曲酮微球
JP7600264B2 (ja) 2020-04-23 2024-12-16 ユニヴァーシティ オブ アイオワ リサーチ ファウンデーション Ｇｐｅｒタンパク質分解ターゲティングキメラ
WO2022040564A1 (en) 2020-08-21 2022-02-24 University Of Iowa Research Foundation Cationic nanoparticle adjuvants
WO2022047201A1 (en) 2020-08-27 2022-03-03 University Of Iowa Research Foundation Gene knock-out for treatment of glaucoma
CN112245434A (zh) * 2020-11-09 2021-01-22 深圳善康医疗健康产业有限公司 一种纳曲酮和利培酮复方缓释组合物
US20240100183A1 (en) 2020-12-11 2024-03-28 University Of Iowa Research Foundation Compositions comprising molecules for cystic fibrosis treatment
EP4340894A1 (de) 2021-05-21 2024-03-27 University Of Iowa Research Foundation Antioxidationsmittelhaltige partikel und verfahren zur verwendung
WO2022271951A1 (en) 2021-06-23 2022-12-29 University Of Iowa Research Foundation Sustained release formulations comprising a selective androgen receptor modulator
US12465564B2 (en) 2021-10-25 2025-11-11 Aquestive Therapeutics, Inc. Oral and nasal compositions and methods of treatment
WO2024197165A1 (en) 2023-03-21 2024-09-26 University Of Iowa Research Foundation Broad spectrum antifungal keto-alkyl-pyridinium compounds
WO2024233783A1 (en) 2023-05-09 2024-11-14 Cornell University Expression cassette coding for vascular endothelial growth factor
WO2025213111A2 (en) 2024-04-05 2025-10-09 Cornell University Aav expression of mirna to suppress human apoe mrna

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL137652C (de) 1962-07-11
BE744162A (fr) 1969-01-16 1970-06-15 Fuji Photo Film Co Ltd Procede d'encapsulage
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
DE2010115A1 (de) 1970-03-04 1971-09-16 Farbenfabriken Bayer Ag, 5090 Leverkusen Verfahren zur Herstellung von Mikrogranulaten
JPS523342B2 (de) 1972-01-26 1977-01-27
GB1413186A (en) 1973-06-27 1975-11-12 Toyo Jozo Kk Process for encapsulation of medicaments
JPS523653A (en) 1975-06-27 1977-01-12 Fuji Photo Film Co Ltd Process for producing fine polymer particles
US4384975A (en) 1980-06-13 1983-05-24 Sandoz, Inc. Process for preparation of microspheres
US4389330A (en) 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
US4530840A (en) 1982-07-29 1985-07-23 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4804663A (en) 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
IE59361B1 (en) 1986-01-24 1994-02-09 Akzo Nv Pharmaceutical preparation for obtaining a highly viscous hydrogel or suspension
AU2810189A (en) 1987-10-30 1989-05-23 Stolle Research & Development Corporation Low residual solvent microspheres and microencapsulation process
US5158952A (en) 1988-11-07 1992-10-27 Janssen Pharmaceutica N.V. 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use
IL92344A0 (en) 1989-01-04 1990-07-26 Gist Brocades Nv Microencapsulation of bioactive substances in biocompatible polymers,microcapsules obtained and pharmaceutical preparation comprising said microcapsules
ES2084698T5 (es) 1989-05-04 2005-03-01 Southern Research Institute Procedimiento de encapsulacion.
US5478564A (en) 1990-02-22 1995-12-26 Teva Pharmaceutical Industries, Ltd. Preparation of microparticles for controlled release of water-soluble substances
IT1243390B (it) 1990-11-22 1994-06-10 Vectorpharma Int Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione.
US5486362A (en) * 1991-05-07 1996-01-23 Dynagen, Inc. Controlled, sustained release delivery system for treating drug dependency
HU222501B1 (hu) 1991-06-28 2003-07-28 Endorecherche Inc. MPA-t vagy MGA-t tartalmazó nyújtott hatóanyag-felszabadulású gyógyászati készítmény és eljárás előállítására
US5658593A (en) 1992-01-16 1997-08-19 Coletica Injectable compositions containing collagen microcapsules
DK0632820T3 (da) 1992-02-28 2000-10-02 Collagen Corp Højkoncentrerede, homogeniserede collagensammensætninger
US5656297A (en) 1992-03-12 1997-08-12 Alkermes Controlled Therapeutics, Incorporated Modulated release from biocompatible polymers
WO1993017668A1 (en) * 1992-03-12 1993-09-16 Alkermes Controlled Therapeutics, Inc. Controlled release acth containing microspheres
FR2692147B1 (fr) * 1992-06-15 1995-02-24 Centre Nat Rech Scient Microsphères en polymère biorésorbable exemptes de tensioactif, leur préparation et leur application comme médicament.
DK0669128T3 (da) 1992-11-17 2000-06-19 Yoshitomi Pharmaceutical Sustained-release mikrosfære indeholdende antipsykotikum og fremgangsmåde til at fremstille samme
JPH08503950A (ja) 1992-12-02 1996-04-30 アルカーメス・コントロールド・セラピユーテイクス・インコーポレーテツド 徐放性成長ホルモン含有マイクロスフェア
EP2275089A1 (de) * 1993-11-19 2011-01-19 Alkermes Controlled Therapeutics, Inc. Herstellung biologisch abbaubarer Mikropartikel, die einen biologisch aktiven Stoff enthalten
CN1074923C (zh) 1993-11-19 2001-11-21 詹森药业有限公司 微囊密封的3-哌啶基取代的1,2-苯并异唑类和1,2-苯并异噻唑类
US5650173A (en) 1993-11-19 1997-07-22 Alkermes Controlled Therapeutics Inc. Ii Preparation of biodegradable microparticles containing a biologically active agent
US5904935A (en) 1995-06-07 1999-05-18 Alza Corporation Peptide/protein suspending formulations
US5747058A (en) 1995-06-07 1998-05-05 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
US5942253A (en) 1995-10-12 1999-08-24 Immunex Corporation Prolonged release of GM-CSF
US5792477A (en) 1996-05-07 1998-08-11 Alkermes Controlled Therapeutics, Inc. Ii Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent
GB9718986D0 (en) 1997-09-09 1997-11-12 Danbiosyst Uk Controlled release microsphere delivery system
US6306425B1 (en) * 1999-04-09 2001-10-23 Southern Research Institute Injectable naltrexone microsphere compositions and their use in reducing consumption of heroin and alcohol
US6331317B1 (en) * 1999-11-12 2001-12-18 Alkermes Controlled Therapeutics Ii Inc. Apparatus and method for preparing microparticles
US6495166B1 (en) * 1999-11-12 2002-12-17 Alkermes Controlled Therapeutics Inc. Apparatus and method for preparing microparticles using in-line solvent extraction
US6264987B1 (en) * 2000-05-19 2001-07-24 Alkermes Controlled Therapeutics Inc. Ii Method for preparing microparticles having a selected polymer molecular weight

Also Published As

Publication number Publication date
EP1925297B1 (de) 2012-07-11
US6534092B2 (en) 2003-03-18
EP1925297A1 (de) 2008-05-28
ES2391315T5 (es) 2017-12-20
DK1925297T4 (da) 2017-11-06
DK1925297T3 (da) 2012-10-08
JP4903344B2 (ja) 2012-03-28
ES2391315T3 (es) 2012-11-23
CY1113082T1 (el) 2016-04-13
US20020119203A1 (en) 2002-08-29
AU5546501A (en) 2001-12-03
WO2001089482A2 (en) 2001-11-29
EP1282404B1 (de) 2008-07-02
AU2001255465B2 (en) 2004-09-23
PT1282404E (pt) 2008-07-16
US20030211164A1 (en) 2003-11-13
CA2405787A1 (en) 2001-11-29
DE60134640D1 (de) 2008-08-14
US20080058502A1 (en) 2008-03-06
US6264987B1 (en) 2001-07-24
WO2001089482A3 (en) 2002-02-21
EP1282404A2 (de) 2003-02-12
EP2258348A2 (de) 2010-12-08
JP2003534268A (ja) 2003-11-18
CA2405787C (en) 2011-06-14
US20020001621A1 (en) 2002-01-03
EP1925297B2 (de) 2017-08-16
CY1110403T1 (el) 2015-04-29
DK1282404T3 (da) 2008-09-01
EP2258348A3 (de) 2011-10-05
US6379704B2 (en) 2002-04-30
ES2305071T3 (es) 2008-11-01
US20030143279A1 (en) 2003-07-31
PT1925297E (pt) 2012-10-18

Similar Documents

Publication Publication Date Title
ATE399535T1 (de) Verfahren zur herstellung von mikropartikeln mit einem ausgewählten polymermolekulargewicht
ATE267657T1 (de) Verfahren zur herstellung von freiform-produkten
DE60213380D1 (de) Kontinuierliches verfahren zur herstellung von engeren molekulargewichtverteilungen konjugierten dien-polymeren und dadurch hergestellten produkten
DE69404876D1 (de) Verfahren zur Herstellung von, im wesentlichen Silanol-freien Silikonharzpulvern
DE69921531D1 (de) Kunststoff-Formteil, Verfahren zu seiner Herstellung, Vorrichtung zur Durchführung des Verfahrens und Behälter
DE502004002882D1 (de) Polyamid-Laser-Sinter-Pulver mit einem Metallsalz und einem Fettsäurederivat, Verfahren zur Herstellung und daraus hergestellte Formkörper
DE60110044D1 (de) Teilentwässertes umsetzungsprodukt, verfahren zur herstellung desselben, und dasselbe enthaltende emulsion
DE60202648D1 (de) Verfahren zur Herstellung von kuppelförmigen Gegenständen mit grossem Durchmesser
DE69513458D1 (de) Verfahren zur Herstellung von hochmolekularen Milchsäure-Copolyestern
DE60116810D1 (de) Polyhydroxyalkanoat enthaltend 3-Hydroxythienyl-Alkansäure als Monomer und ein Verfahren zur Herstellung desselben
DE60223565D1 (de) Verfahren zur herstellung von polymerlatexharzpulver
DE60226940D1 (de) Spritzgiessform und Verfahren zur Herstellung von spritzgegossenen Gegenständen
DE59103454D1 (de) Verfahren zur Herstellung von feinteiligen, wasserlöslichen Polymerisaten.
DE60221838D1 (de) Verfahren zur herstellung von aufgeschäumten polypropylenharzteilchen
DE59008005D1 (de) Verfahren zur Herstellung von hochmolekularen Copolyarylensulfiden.
DE50300051D1 (de) Verfahren zur Herstellung von Organopolysiloxanharz
DE59200684D1 (de) Verfahren zur Herstellung von Vinylpolymeren.
DE60219800D1 (de) Verfahren zur herstellung von cilastatin
DE60226310D1 (de) Verfahren zur herstellung von cycloolefinadditionspolymerisat
DE60217249D1 (de) Verfahren zur Herstellung von pressgeformten Gegenständen
ATE480582T1 (de) Verfahren zur herstellung von expandierbaren styrolpolymerisaten
DE60328114D1 (de) Kautschukverstärktes vinylharz, verfahren zur herstellung von kautschukverstärktem vinylharz und kautschukverstärktes vinylharz enthaltende zusammensetzung
DE50110561D1 (de) Non-metallocene, verfahren zur herstellung von diesen und deren verwendung zur polymerisation von olefinen
DE69109171D1 (de) Verfahren zur Herstellung von geformten Kunststoffartikeln.
DE60214739D1 (de) Verfahren zur herstellung von polyacarbonatoligomer und verfahren zur herstellung von polycarbonatharz daraus

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1282404

Country of ref document: EP